chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pt had vaccine friday afternoon was fine  until Saturday around 1 pm she started  to get a rash on her face oNLy. NO wheR eLse. Saw MD who then predcribed prednisone & hydoxizine. Resolved  in two days.
Pt. experienced a vasovagal episode and was assessed by Dr. Pulse Ox applied and reading of 99% obtained.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. Medical history and concurrent conditions were not reported. On 08-SEP-2014, the patient was vaccinated with ZOSTAVAX, 0.65 ml, subcutaneous (strength and lot number were not reported). Secondary therapy were not reported. The pharmacist reported that a patient received a does of ZOSTAVAX on 08-SEP-2014, that had been stored at 34 degrees for 1 hour. No adverse effect reported. Additional information has been requested.
Low grade fever (chills & weakness); Injection site soreness; This is a spontaneous report received from a contactable male consumer (Patient herself) of 48-Year-old received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/lot number: EL3247, Expiration date: unknown) via an unspecified route of administration on right arm on 12Feb2021 01:00PM and first dose (Lot no: EL3247) on 21Jan2021 02:00 PM via unspecified route of administration both as single dose for COVID-19 Immunization. The patient's medical history and concomitant medication were not reported. Historical vaccine included for first dose. Patient was not reported to known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient was not received other vaccines within 4 weeks and within 2 weeks of prior to the COVID vaccine. Post vaccination patient was not tested with covid. On 13Feb2021 12:00pm (24 hours after second dose) patient experienced low grade fever (chills & weakness) and Injection site soreness for 24 hours. Patient did not receive any treatment for the events. Outcome of the event Low grade fever was recovered after approx 8 hrs and Injection site soreness on an unspecified date.  No follow-up attempts are possible. No further information is expected.
Received Imming globulin & RABAVERT on 11/15/08 late pm?  Developed slight HA next couple of days.  On 11/18/08 = 23:30 HA increased, fever 10 degrees, pre-syncope episode. Tylenol taken at home s/s improved.  HA remained.  Seen 11/19/08 for 2nd series RABAVERT.  Dose given = 16:00.  Will determine if RX reoccurs if vaccine caused or immune globulin or other.
ankle is kinda swollen; This is a spontaneous report from a Pfizer Sponsored Program, received by a contactable consumer (patient). A 72-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unknown route, in Jan2021 (a week ago, as reported) at a single dose for COVID-19 immunisation. Relevant medical history included arthritis (he took ibuprofen as needed when he had a flare up). No relevant concomitant medications were provided. After vaccination, patient's ankle is kinda swollen. He clarified that he was not taking ibuprofen since he has had vaccine and he wanted to know if he could retake it. The outcome of the event was unknown.   Information about Lot/Batch has been requested.
administered dose lower than authorized dose of the Moderna COVID-19 bivalent booster/ Patient was administered 0.25 ml instead of 0.5 ml; No adverse event; This spontaneous case was reported by a physician and describes the occurrence of ACCIDENTAL UNDERDOSE (administered dose lower than authorized dose of the Moderna COVID-19 bivalent booster/ Patient was administered 0.25 ml instead of 0.5 ml) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (administered dose lower than authorized dose of the Moderna COVID-19 bivalent booster/ Patient was administered 0.25 ml instead of 0.5 ml) and NO ADVERSE EVENT (No adverse event). At the time of the report, ACCIDENTAL UNDERDOSE (administered dose lower than authorized dose of the Moderna COVID-19 bivalent booster/ Patient was administered 0.25 ml instead of 0.5 ml) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for ACCIDENTAL UNDERDOSE (administered dose lower than authorized dose of the Moderna COVID-19 bivalent booster/ Patient was administered 0.25 ml instead of 0.5 ml).    No concomitant medications were reported.  It was reported that, the nurses had no standing orders other than what they had for the second booster when they first administered Bivalent booster. So, they assumed the same dose as the second booster, hence they had administered 0.25 ml instead of 0.5 ml to uncompromised patient. They administered dose lower than authorized dose of the Moderna COVID-19 bivalent booster. No treatment details were reported.
First dose: Chills; First dose: nausea; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 74-year-old male patient received BNT162b2 (BNT162B2), on 26Feb2021 at 09:00 as dose 1, single (Lot number: EN6202) at the age of 74 years, in left deltoid for covid-19 immunisation. The patient's relevant medical history included: "Triple Bypass", start date: 04Oct2014 (unspecified if ongoing), notes: Triple Bypass He was on a ventilator relative to this.; "COVID", start date: Jan2021 (unspecified if ongoing), notes: COVID Before the first shot he had COVID, a mild case, no fever, no cough. His wife had it a long time long hauler lost her sense of smell for a time.; "blood pressure" (unspecified if ongoing), notes: blood pressure medication Furosemide; "cancer" (unspecified if ongoing), notes: his mother died at 45 from cancer, father had cancer (family medical history). Concomitant medication(s) included: FUROSEMIDE taken for blood pressure abnormal. Vaccination history included: Gamma globulin (Manufacturer/Lot/NDC/Expiry: Unknown, caller did not have this information to provide., Adverse Event: Quite a reaction), administration date: 1968, reaction(s): "Quite a reaction"; Cholera (Manufacturer/Lot/NDC/Expiry: Unknown, caller did not have this information to provide., Adverse Event: Reaction), reaction(s): "Reaction"; Yellow fever (Manufacturer/Lot/NDC/Expiry: Unknown, caller did not have this information to provide.). The following information was reported: CHILLS (non-serious) with onset 27Feb2021 at 01:00, outcome "recovered" (27Feb2021), described as "First dose: Chills"; NAUSEA (non-serious) with onset 27Feb2021 at 01:00, outcome "recovered" (27Feb2021), described as "First dose: nausea".
Right arm extreme pain in the joint and around the area. Muscle weakness. Overall tired and not well. Light fever
Left physical and came home. Next morning, had a usual morning. Went to a doctor's appointment and started to be nauseous; started to feel better. Went to 2nd appointment and still felt bad, sat down until felt better. Drove home and called doctor so doctor called ambulance; based on the symptoms pt was going into anaphylactic shock. Taken to hospital where was admitted, and stayed there. Sent home with meds: Ondansetron, Ketorolac, Albuterol inhaler. Confirmed you had an anaphylactic reaction but they did not specify whether it was related to the vaccine. Immune system was down, so 2 days after developed a cold with chest congestion; took over the counter AIRBORNE. Last week still feeling wiped out, lethargic, appetitive still not back completely, still nursing the effects of what happened. Has a doctor appointment on 12/23 as well as lab work. Has received Flu shot with no problem for the last 10 years. Dad has allergic to eggs so has not received a Flu vaccine.
Central retinal vein occlusion of right eye; Fewer; headache; pain throughout body; fatigue; This is a spontaneous report from a non-contactable consumer (patient). A 38-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EW0173), dose 2 via an unspecified route of administration, administered in right arm on 07May2021 16:00 as 2nd dose, single for covid-19 immunisation. Medical history was reported as none. The patient's concomitant medications were not reported. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EW0161) administered in left arm on 16Apr2021 00:00 for COVID-19 Immunization. There is no other vaccine in four weeks, no other medications in four weeks, no covid prior vaccination, no covid tested post vaccination, no known allergies, no other medical history. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. There is no list of any other medications the patient received within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient experienced central retinal vein occlusion of right eye, Fewer, headache, pain through-out body, fatigue on 08May2021. The adverse event resulted in emergency room/department or urgent care, disability or permanent damage. The outcome of the events was recovered with lasting effects (resolved with Sequel).   No follow-up attempts are possible. No further information is expected.
flu like symptoms; bodyache; slight fever of 100.4 F; tinnitus; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (flu like symptoms), PAIN (bodyache), TINNITUS (tinnitus) and PYREXIA (slight fever of 100.4 F) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028A21A and 025A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Mar-2021, the patient experienced TINNITUS (tinnitus). On 31-Mar-2021, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms), PAIN (bodyache) and PYREXIA (slight fever of 100.4 F). On 01-Apr-2021, INFLUENZA LIKE ILLNESS (flu like symptoms), PAIN (bodyache) and PYREXIA (slight fever of 100.4 F) had resolved. At the time of the report, TINNITUS (tinnitus) had not resolved. Not Provided          Concomitant product use was not provided by the reporter. Treatment information was not provided. Action taken with mRNA-1273 in response to the events were not applicable.
This spontaneous report as received from a other health professional refers to a patient of unknown age. On 09-JUN-2017 the patient was vaccinated with VAQTA lot # N005274 for prophylaxis. On 2017 the patient experienced incorrect product storage. On an unknown date the patient experienced no adverse event. The outcome of incorrect product storage and no adverse event is unknown. The reporter considered incorrect product storage and no adverse event to be not related to VAQTA. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1707USA006507.
This spontaneous report as received from a 59 year old female patient reporting on herself. The patient's historical drugs were not reported. The patient's medical history included parathyroid surgery and flu (reported as "within the last 12 months"). The patient did not have any drug allergy/reaction. The patient's concurrent condition included asthma. Concomitant therapies included ZANTAC and unspecified medication for asthma treatment. On 06-JUN-2018, the patient was vaccinated with PNEUMOVAX 23 intramuscularly, dose and frequency reported as "one injection", for prevention of pneumonia (strength, lot# and expiration date were not reported). On 07-JUN-2018, the patient experienced redness, pain, swelling, and a warm sensation in her upper left arm after getting PNEUMOVAX 23 vaccination (erythema, feeling hot, peripheral swelling and pain in extremity). The patient sought medical attention and contacted an unknown pharmacist for treatment because her nurse practitioner's office was closed. Diagnostic laboratories were not performed. At the time of reporting, the outcome of erythema, feeling hot, peripheral swelling and pain in extremity was not recovered (reported as "present status: yes"). Additionally, the causality assessment between aforementioned events and PNEUMOVAX 23 was not provided.
Redness at site of injection. Rash, minor swelling. Normal pain associated with local site injection. No major pain otherwise stated. Since both the pneumonia/flu vaccines were administered in the same arm, it is difficult to determine which product caused the reaction.
1640 after pt received the COVID-19 vaccine Moderna, pt became nauseated and started dry heaving. Stated she feels slightly dizzy. Pt held for 30 minutes w/ assistance until comfortable.
This spontaneous report as received from a physician, via company representative, refers to a 15 year old male patient. Patient's concurrent conditions and medical history was not known. On 10-NOV-2014, the patient was vaccinated with the first dose of GARDASIL injection and on 19-JAN-2015, patient received the second dose of GARDASIL, intramuscularly. Concomitant medications were not provided. On 22-JAN-2015, the patient experienced encephalitis (hospitalization, medically significant and life threatening). On that day, patient's parents stated that the patient was 'lying around', was not active and was not himself. On 23-JAN-2015, at 15:30 hours, the patient was found unconscious and unresponsive on his bedroom floor. The patient was taken to emergency room and was then hospitalized. Unspecified testing was conducted at that hospital. The patient had a follow up appointment with the physician who stated that the unspecified tests came back negative. The outcome of encephalitis was unknown. Causality assessment was not provided. The reporter considered encephalitis to be life threatening. Upon internal review, encephalitis was considered to be medically significant. Additional information has been requested.
Pt presented after receiving vaccine on 12/21/2020 on 12/31/2020 with Bell's palsy.  Right sided facial perceived numbness and numbness of right arm distal from site of vaccine.  No weakness on exam, +weakness perceived by patient.  Reported by patient these symptoms improved from date of vaccination.  Able to fully open and close right eye.  No facial droop.  She states these symptoms occured 5 minutes after having vaccine, but initially dismissed as her anxiety about getting  vaccinated.
slightly tender arm; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (slightly tender arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027A21A and 039K20A) for COVID-19 vaccination.     The patient's past medical history included Asthma chronic (Worsened after 1st COVID vaccine) since an unknown date. Concurrent medical conditions included Pollen allergy and Drug allergy (sulfa). Concomitant products included CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for an unknown indication.   On 08-Jan-2021 at 3:24 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021 at 11:10 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced TENDERNESS (slightly tender arm). At the time of the report, TENDERNESS (slightly tender arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Jan-2021, Blood pressure measurement: (Inconclusive) result not mentioned. On 08-Jan-2021, Heart rate: 100-115 for a period of 2 hours.         Patient took concomitant drug Zyrtec once prior to her second vaccine. No treatment information was provided.  Event occurred after the second vaccine administration.  Action taken with mRNA-1273 in response to the event was not applicable.; Sender's Comments:
The night after receiving the vaccine he developed hematuria. This continued until his second dose of vaccine. After the second dose of vaccine, the hematuria worsened so much so that he was just leaking blood from the urethra even without urination. With urination he was passing frank blood and clots.  He stopped clopidogrel and aspirin and it totally resolved.  He underwent cystoscopy and there were no lesions identified.  He resumed clopidogrel and aspirin and has not had any more bleeding.
patient had swelling and rash down upper arm from injection site down to elbow. with itching.. and redness
Patient was observed post Covid-19 immunization for 15 minutes .  During the observation period, she experienced an adverse reaction with the following symptoms:  metallic taste, headache.   Assessment : Time of assessment 1036. Alert and oriented. Patient reported symptoms above with a headache a 3 out of 10 during her 15 minute observation. She says she has phlegm at the back of her throat since receiving the vaccine today. Her swallowing is fine as she drank water without incident.  1036: BP 108/43; P 85, Sat 100% RA 1040: BP 112/56, P 83, Sat 100% RA reports a cough since receiving vaccine. 1049: BP 120/64 standing. Reports no headache and the metallic taste is no longer as noticeable since drinking water.   Actions taken:  Vitals sign taken  form obtained and completed Nurse. Water given.   Medications administered: No medication administered.   Disposition: Reports no further symptoms of adverse reaction after observation for additional 15 minutes minutes. Discharged home. Instructed to call 911 for trouble breathing, rapid heart rate, dizziness, swelling of tongue or throat.
I had an asthma attack and there was an unknown trigger for it. I went to Urgent Treatment Center on 11/16/2021. I was prescribed oral prednisone and I had a breathing treatment done when I was at the Emergency Room. On 11/19/2021, I went to the ER again. I received another breathing treatment and oral prednisone.
Severe localized inflammatory signs from left shoulder to elbow and generalized malaise, shaking, chills, fever, nausea, vomiting symptoms started 7 hours after vaccination.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On an unknown date in 2012, the patient was inoculated with ZOSTAVAX (lot number, dosage and route of administration not provided), as recommended for routine adult health maintenance for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster, also known as shingles and other complications. On an unknown date in 2016, the patient was treated for a blistering vesicular outbreak that was diagnosed as severe herpes zoster or shingles. The outcome of the events is unknown. As a direct and proximate result of ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for the long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Initial report received on 04 December 2006 from a health care professional. A 53-year-old male patient, with unknown medical history, had received a dose of FLUZONE SV '2006-'2007 USP, lot number U2184AA on an unspecified date. Reportedly, several hours post-immunization, the patient experienced ventricular tachycardia and a seizure.  The patient was subsequently hospitalized (dates not reported). Treatments received and diagnostic tests performed were reported as unknown.
This case was reported by a health professional to a distributor and described the occurrence of an injection site reaction in a male child who received diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Infanrix). On 14Apr04, the pt received the fourth dose of Infanrix (lot DTPA622A2). At an unspecified time following the administration of Infanrix, on 14Apr04, the pt experienced an injection site reaction characterized by swelling, warmth, redness and induration. The pt was seen at a physician office. The event was unresolved. The health professional considered the injection site reaction to probably be related to vaccination with Infanrix.
PATIENT GOT A SUNBURN ON SUNDAY PRIOR TO WEDNESDAY OF EVENT; HER RIGHT LEG GOT EXTREMELY SWOLLEN; WENT TO URGENT CARE AND WAS SENT TO EMERGENCY ROOM TO CHECK FOR BLOOD CLOT SKIN COLOR WAS PUPLE/RED - NO RASH; BLOOD CLOT NOT FOUND - CAUSE OF SWELLING NOT FOUND SWELLING RESOLVED ITSELF ABOUT 5 DAYS; FRIEND OF PATIENT GOT SWOLLEN FOOT AND SAME RED/PURPLE SKIN TONE AFTER SECOND VACCINE AND SUNBURN - SAME TREATMENT COURSE - WE HAVE PHOTOS OF BOTH EVENTS.
15 scattered chicken pox vesicles mostly on anterior trunk; some fresh others resolving; no frank scabs; also with URI sxs exposed 2 wks prior to cousin w/ chicken pox.
This spontaneous report was received from an officer manager via a company representative and refers to an unspecified number of anonymous patients of unknown age and gender. The patients' medical history and concurrent conditions were not reported. On an unknown date, the patients were vaccinated with improperly stored doses of VARIVAX (route of administration, lot numbers and expiry dates were not reported). It was reported that, VARIVAX was stored at 40 degrees Fahrenheit for 72 continuous hours on unspecified dates. Concomitant therapy was not reported. No adverse effect was reported. Additional information has been requested.
TIAStroke numbness of R face and RUE Narrative: I recommended transfer via 911 from clinic to nearest ER; she refused and signed out against medical advice. She plans to go to ER by private vehicle driven by a friend.
PATIENT PRESENTED TO THE PHARMACY WITH LARGE RASH THAT COVERED HER UPPER ARM. RASH WAS SLIGHTLY INFLAMED AND RED. PATIENT DENIES FEELING FEVERISH OR DIFFICULTY BREATHING. PATIENT STATED THAT SYMPTOMS PRESENTED THREE DAYS AGO AND IT DOESN'T HURT BUT REALLY ITCHES. SHE RELAYED THAT SHE RECEIVED NUMEROUS SHOTS THE FOLLOWING WEEKEND. PATIENT NOT IN DISTRESS AND DISPLAYED NO OTHER SYMPTOMS.
Pt recvd Engerix-B on 15JUL92, 19AUG91, & 25JAN92 & 31MAR92 titer levels revealed pt had not sseroconverted;
15 days p/vax pt devel low grade fever & parotitis which persisted until today (6 days);also devel orchitis 17 days p/vax;fever 100-102, pharyngitis, enlarged cervical lymph nodes;h/a, last 6 days top of head, loss appetite, malaise;
Patient woke up Monday morning complaining of symptoms of body ache, fever, chills, headache, rapid heart rate, and swelling in armpit. The pain in armpit swelling escalated and was visibly swollen. Patient had over 100 degree F fever. Patient went to ER. ER ran EKG, bloodwork, and ultrasound. Provider found patient has swollen lymph nodes and her allergies were escalated in reaction to the vaccine. ER doctor prescribed ibuprofen, zpak, flonase, and allegra. Patient is taking claritin for heightened allergies.